Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis.

ABSTRACT:

Introduction

The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study.

Methods

Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo.

Results

A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079).

Discussion

Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.

SUBMITTER: Hirano I 

PROVIDER: S-EPMC10045973 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature